Concanavalin A can be coupled to agarose to form Concanavalin A (agarose) (HY-P2149A). Concanavalin A (ConA) is a selective, competitive binding agent that targets specific carbohydrate structures containing glucose and mannose; it acts as a mitogen and exhibits varying degrees of cytotoxicity, hepatotoxicity, and teratogenicity. Concanavalin A is also utilized for in vivo blood glucose monitoring in the context of diabetes^[1][2][3][4].

Concanavalin A (3-6 μg/mL) induces mitosis in B and T cells and promotes DNA synthesis^[1].
Concanavalin A (25 μg/mL) induces cytokine interferon production in C57BL/6 mouse splenocytes^[1].
Concanavalin A (12 μg/mL) exhibits non-specific cytotoxicity against human T lymphocyte subsets expressing the Leu-7 antigen, but not against other T cell subsets^[1].
Treatment of 8-day-old rat embryos with Concanavalin A (12.5, 25, 50, 100 μg/mL; 72 hours) resulted in a concentration-dependent decrease in embryo survival rate, yolk sac diameter, crown-rump length, and somite number, and an increased incidence of morphological abnormalities such as neural tube defects^[1].
Concanavalin A also enhances the proliferation of human thymocytes cultured with IL-2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Concanavalin A (20 mg/kg; i.v.) induces autoimmune hepatitis in mice^[3].
Concanavalin A (1-4 mg, 7-15 mg; i.v.; single dose) in a rabbit model: the low-dose group (1-4 mg) showed no obvious symptoms, the 7 mg dose caused death in the rabbit model, and the 15 mg dose induced intravascular erythrocyte agglutination in rabbits^[1].
Concanavalin A (400 μg/mouse, 800 μg/mouse; i.v.; single dose) in normal B6D2F1, BALB/c, C3H, and Akr strain mice: 400 μg (20 mg/kg) caused liver damage, spleen and thymus atrophy, and pulmonary congestion; liver tissue basically recovered to normal after 15 days, with no significant abnormalities after 30 days; 800 μg (40 mg/kg) could cause 30% of mice to die within 2 days due to acute liver failure^[1].
Concanavalin A (2000 μg/mouse; i.p.; single dose;) induced white amorphous substance masses in the peritoneal cavity of normal B6D2F1, BALB/c, C3H, and Akr strain mice, without liver damage or animal death^[1].
Concanavalin A (500 μg/mouse; i.v.; single dose) in a normal CBA mouse model led to increased ConA concentrations in blood, liver, lymph nodes, and spleen, resulting in lymphotoxicity, perisplenic follicular protein deposition, and hepatic parenchymal damage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

11028-71-0

Solid

White to light yellow

[Concanavalin A]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ballerstadt R, et al. Concanavalin A for in vivo glucose sensing: a biotoxicity review. Biosens Bioelectron. 2006 Aug 15;22(2):275-84.  [Content Brief]

  [2]. Li W, et, al. Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun. 2011 Oct 22;414(2):282-6.  [Content Brief]

  [3]. Cantelli A, et al. Concanavalin A-Rose Bengal bioconjugate for targeted Gram-negative antimicrobial photodynamic therapy. J Photochem Photobiol B. 2020 Mar 13;206:111852.  [Content Brief]

  [4]. Zhou Y, et al. The Protective Effect of Resveratrol on Concanavalin-A-Induced Acute Hepatic Injury in Mice. Gastroenterol Res Pract. 2015;2015:506390.  [Content Brief]